Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seer Inc SEER

Technology Scientific & Technical Instruments
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution... see more

Recent & Breaking News (NDAQ:SEER)

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

GlobeNewswire February 1, 2024

Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference

GlobeNewswire December 21, 2023

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

GlobeNewswire November 10, 2023

Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500

GlobeNewswire November 8, 2023

Seer Reports Third Quarter 2023 Financial Results

GlobeNewswire November 7, 2023

Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program

GlobeNewswire November 1, 2023

Seer to Report Third Quarter 2023 Financial Results on November 7, 2023

GlobeNewswire October 19, 2023

Seer to Participate in Upcoming September Investor Conferences

GlobeNewswire September 8, 2023

Seer Reports Second Quarter 2023 Financial Results

GlobeNewswire August 8, 2023

Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference

GlobeNewswire July 27, 2023

Seer to Report Second Quarter 2023 Financial Results on August 8, 2023

GlobeNewswire July 13, 2023

Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center

GlobeNewswire June 7, 2023

Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies

GlobeNewswire June 1, 2023

Seer Reports First Quarter 2023 Financial Results

GlobeNewswire May 9, 2023

Seer to Report First Quarter 2023 Financial Results on May 9, 2023

GlobeNewswire April 20, 2023

Seer's Proteograph(TM) Product Suite identifies undiscovered links between protein variants and lung cancer progression

GlobeNewswire March 29, 2023

Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook

GlobeNewswire March 2, 2023

Seer to Present at the Cowen 43rd Annual Health Care Conference

GlobeNewswire February 21, 2023

Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

GlobeNewswire February 9, 2023

Seer to Present at the J.P. Morgan 41st Annual Health Care Conference

GlobeNewswire December 27, 2022